文献速递银屑病与炎症性皮肤病

IL-23-TH17轴作为毛发红糠疹治疗靶点

Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris.
PubMed 文献 · JAMA Dermatol · 2017-01-01

本病例报告发现毛发红糠疹(PRP)皮损中多种促炎细胞因子表达上调,尤其TH17细胞因子IL-17A、IL-17F和IL-22。一例PRP患者接受乌司奴单抗治疗后2周皮损消退,1个月几乎完全缓解,临床和组织病理改善与TH17细胞因子表达水平平行。提示IL-23-TH17轴在PRP发病中起作用,为难治性PRP提供靶向治疗依据。

要点

  • PRP皮损中TH17细胞因子IL-17A、IL-17F、IL-22表达增加。
  • 乌司奴单抗治疗PRP 2周皮损消退,1个月几乎完全缓解。
  • 临床改善与TH17细胞因子表达平行,与IFN-γ和TNF滞后。

核心结论

  • IL-23-TH17轴在PRP发病中起作用,与银屑病共享致病炎症通路。
  • 靶向IL-23-TH17通路可作为难治性PRP的治疗选择。

研究设计与样本

  • 病例报告:一例PRP患者接受乌司奴单抗治疗,另两例难治性PRP患者提供皮损活检。
  • 比较PRP、银屑病和健康供者皮肤样本的促炎细胞因子mRNA表达。
  • 一例患者治疗前及治疗后4周和28周取皮损样本,随访6个月。

主要发现

  • PRP皮损中多数先天免疫促炎细胞因子表达上调,包括TNF、IL-6、IL-12、IL-23和IL-1β。
  • 适应性T细胞因子中,TH1细胞因子和尤其TH17细胞因子IL-17A、IL-17F、IL-22增加。
  • 乌司奴单抗治疗2周皮损消退,1个月几乎完全缓解。
  • 临床和组织病理改善与TH17细胞因子表达水平平行,但干扰素-γ和TNF滞后于改善。

关键数值与推荐

  • 乌司奴单抗皮下注射45 mg,第0和4周给药,之后每季度一次。

临床怎么用

  • 对难治性PRP可考虑靶向IL-23-TH17通路治疗。
  • 乌司奴单抗可能有效,但需更多研究验证。

局限性

  • 病例报告,样本量小,结论需进一步验证。
  • 仅一例患者接受治疗,疗效证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Treatment of pityriasis rubra pilaris (PRP) is solely based on its resemblance to psoriasis rather than any knowledge of its pathomechanism. Insight into pathogenic mediators of inflammation is essential for targeted and valid treatment options that could replace previous serendipitous therapeutic approaches in refractory PRP. OBJECTIVE: To determine whether blockade of the interleukin 23-helper T cell 17 (IL-23-TH17) pathway with ustekinumab represents an efficacious and, based on its proinflammatory cytokine profile, targeted treatment option in PRP. DESIGN, SETTING, AND PARTICIPANTS: In this case report, a patient with PRP received outpatient treatment at a university hospital department of dermatology with ustekinumab according to the dosing regimen approved for psoriasis. Lesional skin biopsy samples were taken from this patient and 2 others with refractory PRP. Messenger RNA (mRNA) expression of proinflammatory innate and T-cell-derived cytokines were measured and compared with skin samples from patients with psoriasis and healthy donors. From 1 patient, lesional skin samples were taken before ustekinumab treatment and 4 and 28 weeks after treatment initiation. Follow-up was completed after 6 months. INTERVENTION: Subcutaneous ustekinumab, 45 mg, at weeks 0 and 4 and quarterly thereafter. MAIN OUTCOMES AND MEASURES: The primary outcome was to determine the changes in expression of proinflammatory innate and T-cell-derived cytokines during ustekinumab therapy. The secondary objective was to evaluate the clinical and histopathologic phenotype in relation to the mRNA expression profile of proinflammatory cytokines. RESULTS: In lesional PRP skin samples from a single patient, upregulated expression levels were found for most proinflammatory innate cytokines, including tumor necrosis factor (TNF), IL-6, IL-12, IL-23, and IL-1β. Among adaptive T-cell cytokines, an increase of TH1 cytokines and, in particular, TH17 cytokines IL-17A, IL-17F, and IL-22 was seen in PRP. The patient with PRP who received ustekinumab showed regression of skin lesions after 2 weeks and almost complete resolution after 1 month. Clinical and histopathologic improvement paralleled the expression levels of TH17 cytokines but not of interferon-γ and TNF, which lagged behind the amelioration. CONCLUSIONS AND RELEVANCE: In this case report, a role of the IL-23-TH17-axis in PRP was identified, suggesting a shared pathogenic inflammatory pathway with psoriasis, despite evident clinical and histopathologic differences. In addition, this report provides a rationale for targeting the IL-23-TH17-pathway as a treatment option for refractory PRP.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Feldmeyer L, Mylonas A, Demaria O, et al. Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris. JAMA Dermatol. 2017. PMID: 28122069. doi:10.1001/jamadermatol.2016.5384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。